» Articles » PMID: 32533544

Prognostic Value of Serially Estimated Serum Procalcitonin Levels in Traumatic Brain Injury Patients With or Without Extra Cranial Injury on Early In-hospital Mortality: A Longitudinal Observational Study

Overview
Journal Neurocrit Care
Specialty Critical Care
Date 2020 Jun 14
PMID 32533544
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Traumatic brain injury (TBI) is associated with majority of trauma deaths, and objective tools are required to understand the severity of injury. The application of a biomarker like procalcitonin (PCT) in TBI may allow for assessment of severity and thus aid in prognostication and correlation with mortality and outcome.

Aims: The primary objective is to determine the correlation between PCT concentrations with TBI outcomes (mainly in terms of mortality) at intensive care unit (ICU)/hospital discharge. Secondary objectives are to evaluate correlation with associated extra cranial injuries and complications during hospital stay.

Methods: In total, 186 TBI patients aged > 18 years with minimum survival for at least 12 h admitted to the ICU at the level 1 trauma center were prospectively included in the study and divided into two groups: TBI with and without extra cranial injuries. All admitted patients were treated according to the standard institutional protocol. The PCT levels were obtained on admission, on day 2, and 5. Clinical, laboratory, diagnostic, and therapeutic data were also collected. Primary mortality is defined as death related to central nervous system (CNS) injury, while secondary mortality defined as death related to sepsis or extracranial cause.

Results: Median PCT levels at admission, day 2, and day 5 in TBI patients with extracranial injuries were 3.0, 0.83, and 0.69 ng/ml. In total, primary mortality was observed in 18 (9.7%) patients, while secondary causes were attributable in 20 (12.3%) patients. Regression analysis for primarily CNS cause of mortality showed PCT cutoff level at admission more than 5.5 ng/ml carried sensitivity and specificity of 75%, but for secondary cause (sepsis) of mortality, PCT cutoff values on day 2 > 1.15 ng/ml were derived significant with sensitivity of 70% and specificity of 66%. No significant association of parameters like length of ICU stay, Glasgow outcome scale (GOS), and primary/secondary mortality with the presence of extracranial injuries in TBI patients as compared with TBI alone was noted.

Conclusion: This observational study demonstrates the poor correlation between PCT concentrations with outcome at days 1, 2, and 5 post-injury. The predicted relationship between PCT levels and outcome was not confirmed, and that these results do not support the prognostic utility of PCT biomarker in this population for outcome (mortality) assessment in TBI patients with or without extracranial injuries.

Citing Articles

Predictive value of the serum procalcitonin level for fulminant virus-associated encephalopathy.

Huang L, Yang X, Li J, Peng S BMC Pediatr. 2024; 24(1):831.

PMID: 39716119 PMC: 11665223. DOI: 10.1186/s12887-024-05335-4.


Association of initial assessment variables and mortality in severe pediatric traumatic brain injury.

Bergus K, Patterson K, Asti L, Bricker J, Beyene T, Schulz L World J Pediatr Surg. 2024; 7(2):e000718.

PMID: 38818384 PMC: 11138288. DOI: 10.1136/wjps-2023-000718.


Procalcitonin/Albumin Ratio Predicts the Outcome After Severe Traumatic Brain Injury: A Propensity Score-Matched Analysis.

Sun M, Gu L, Li Y, Luo F, Tao Y, Shen W Neurocrit Care. 2023; 40(2):664-673.

PMID: 37523109 DOI: 10.1007/s12028-023-01792-4.


Prognostic Value of Serum Procalcitonin Based Model in Moderate to Severe Traumatic Brain Injury Patients.

Wang R, Hua Y, He M, Xu J J Inflamm Res. 2022; 15:4981-4993.

PMID: 36065318 PMC: 9440674. DOI: 10.2147/JIR.S358621.


C-reactive protein-albumin ratio and procalcitonin in predicting intensive care unit mortality in traumatic brain injury.

Gursoy C, Gursoy G, Gumus Demirbilek S Acute Crit Care. 2022; 37(3):462-467.

PMID: 35977896 PMC: 9475143. DOI: 10.4266/acc.2022.00052.


References
1.
Balci C, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B . Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care. 2003; 7(1):85-90. PMC: 154110. DOI: 10.1186/cc1843. View

2.
Reith H, Mittelkotter U, Debus E, Kussner C, Thiede A . Procalcitonin in early detection of postoperative complications. Dig Surg. 1998; 15(3):260-5. DOI: 10.1159/000018625. View

3.
Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M . Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363(9409):600-7. DOI: 10.1016/S0140-6736(04)15591-8. View

4.
Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret G . Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006; 34(7):1996-2003. DOI: 10.1097/01.CCM.0000226413.54364.36. View

5.
Becker K, Snider R, Nylen E . Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2009; 159(2):253-64. PMC: 2825349. DOI: 10.1111/j.1476-5381.2009.00433.x. View